Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

Market Cap	20.19B
Revenue (ttm)	8.04B
Net Income (ttm)	932.37M
Shares Out	770.09M
EPS (ttm)	1.21
PE Ratio	24.79
Forward PE	20.33
Dividend	1.28 (4.27%)
Ex-Dividend Date	Jul 12, 2024

Volume	4,338,300
Average Volume	4,860,616
Open	30.08
Previous Close	30.23
Day's Range	29.96 - 30.58
52-Week Range	26.16 - 39.05
Beta	0.80
RSI	40.04
Earnings Date	Mar 31, 2025

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600329

Financial Performance

In 2023, SHA:600329's revenue was 8.22 billion, a decrease of -0.33% compared to the previous year's 8.25 billion. Earnings were 986.71 million, an increase of 14.49%.